newsfilter
← Latest News
GlobeNewswire·

argenx Completes Acquisition of Forte Biosciences, Inc.

Acquisition adds first-in-class anti-CD122 Antibody, FB102, to argenx’s immunology pipeline August 27, 2026 – 8:50 AM ET Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology